, and Itsuo Kodama. Ca v3.2 subunit underlies the functional T-type Ca 2ϩ channel in murine hearts during the embryonic period.
TWO DISTINCT FAMILIES of voltage-gated Ca 2ϩ channels (Ca v ) are identified in mammalian cardiac muscle: high-voltage-activated L-type Ca 2ϩ channels and low-voltage-activated T-type Ca 2ϩ channels (10) . The L-type Ca 2ϩ channels exist in large quantities in working myocardium and play an essential role in the excitation-contraction coupling by mediating plasma membrane Ca 2ϩ influx required for Ca 2ϩ -induced Ca 2ϩ release (1) . In contrast, less information is available regarding the expression and function of T-type Ca 2ϩ channels. T-type Ca 2ϩ current (I Ca,T ) is observed in pacemaker cells from the sinoatrial node (8, 35) and Purkinje fibers (9) . I Ca,T is clearly described in embryonic (12) or neonatal cultured atrial and ventricular myocytes (17) , whereas it is rarely observed in normal adult ventricular myocytes (19) . I Ca,T has been shown to reappear in ventricular myocytes under some pathological processes, such as ventricular hypertrophy (19, 24) and postmyocardial infarction (11) . These facts suggest that T-type Ca 2ϩ channels are associated with pacemaker activity, development, and postnatal growth of cardiac cells.
Recent advances in molecular and genetic characterization have identified three different subtypes of gene encoding ␣ 1 -subunits of T-type Ca 2ϩ channels: Ca v 3.1, Ca v 3.2, and Ca v 3.3 (2, 15, 25) . The functional expression of these cDNAs in heterologous systems generated currents analogous to native I Ca,T in terms of voltage dependence and kinetics of activation and inactivation, but they are not identical (13, 21) . Whereas Ca v 3.3 was mostly detected in the brain (15) , Ca v 3.1 and Ca v 3.2 mRNAs were also detected in human, rat, and mouse hearts (2, 25) . The subtype distribution is also development stage dependent (22) , but the issue remains controversial. Cribbs et al. (3) have shown in mouse embryonic hearts that only Ca v 3.1 underlies functional T-type Ca 2ϩ channels in midgestational (E14) fetal myocardium. In rat hearts at middleto-late embryonic (E16 -21) and perinatal periods, substantial participation of both Ca v 3.1 and Ca v 3.2 to the functional T-type Ca 2ϩ channels has been reported (7). To our knowledge, no data are available for the subtype-specificity of functional T-type Ca 2ϩ channels at earlier embryonic stages of mammalian hearts.
In the present study, we investigated developmental changes of subtype expression for the functional T-type Ca 2ϩ channels in mouse hearts from the earliest embryonic stage at which the heart starts to beat regularly (E9.5) to adulthood. Our observations in cell electrophysiology and mRNA quantification have revealed that Ca v 3.2 underlies the functional T-type Ca 2ϩ channels in the embryonic murine heart, and there is a subtype switching of transcripts from Ca v 3.2 to Ca v 3.1 in the perinatal period.
METHODS

Animals
. ICR mice at three developmental stages were employed for the present study: an early and a late embryonic day (E9.5 and E18) and 10-wk-old female adult. All animal procedures were approved by the Animal Care and Use Committee, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan.
Dissection of ventricles from E9.5 mouse embryos. Pregnant (9.5 days postcoitum) mice were euthanized by cervical dislocation, the uteri were isolated, and whole embryos were exposed. The ventricles were separated carefully from tubular hearts with the use of a sharp needle under a stereoscopic microscope. During the dissection procedure, the tissues were kept in Hanks' balanced salt solution (Sigma; St. Louis, MO).
Electrophysiological recordings. Single myocytes were prepared from ventricles of E9.5, E18, and adult mice by methods previously described (18, 34) . Whole cell Ca 2ϩ currents were recorded from the myocytes using the patch-clamp technique. All experiments were carried out at 32-35°C. To isolate Ca 2ϩ currents, the myocytes were perfused with Na ϩ -and K ϩ -free external solution containing (in mM) 140 TEA-Cl, 1 MgCl2, 5 HEPES, 10 glucose, 5 CaCl2, 5 4-aminopyridine, and 0.005 tetrodotoxin (pH 7.4 with CsOH). The internal pipette solution contained (in mM) 60 CsOH, 80 CsCl, 40 aspartate, 5 HEPES, 10 EGTA, 5 MgATP, 5 Na 2-creatine phosphate, and 0.65 CaCl2 (pH 7.2 with CsOH). The recording pipettes had tip resistances ranging from 3.8 to 4.5 M⍀ when filled with the internal solution. Liquid junction potential of the internal pipette solution was minimal (2.0 Ϯ 0.1 mV; n ϭ 6). Therefore, we did not correct the membrane potential (V m) by the liquid junction potential. NiCl2, which blocks Cav3.2-based T-type Ca 2ϩ current at lower concentrations than Ca v3.1-based T-type Ca 2ϩ current (16) , was diluted in the external solution from a stock solution (1 M) to the appropriate concentrations.
Current recordings were made with an Axopatch-200B amplifier (Axon Instruments). Series resistance was compensated for ϳ75%. Command voltage pulse generation and data acquisition were performed with a Digidata 1200 and pCLAMP8 software (Axon Instruments). Cell capacitance was measured by applying a ramp voltage pulse of 0.5 V/s at a potential ranging between Ϫ50 and ϩ70 mV. The average cell capacitance was 25.5 Ϯ 1.6 pF for E9.5 myocytes (n ϭ 10), 28.9 Ϯ 1.8 pF for E18 myocytes (n ϭ 9), and 154.3 Ϯ 10.7 pF for adult myocytes (n ϭ 11).
L-type Ca 2ϩ current (ICa,L) and ICa,T were separated by application of 200-ms voltage steps in 10-mV increments, with a pulse interval of 5 s, to different test potentials from holding potentials (HP) of Ϫ100 and Ϫ50 mV. Isolation of I Ca,T was performed by subtracting the currents obtained from the same test potential taken at the different HPs. Current amplitude was determined as the difference between the peak inward current and the steady-state current recorded at the end of the test pulse. The current amplitude was divided by cell capacitance to obtain current density.
In experiments to study the activation and inactivation properties of I Ca,T, the current was recorded from HP of Ϫ100 mV in the presence of nisoldipine (3 M) to eliminate ICa,L. The voltage-dependence of activation was estimated from conductance (G)-voltage relationship obtained by the equation G ϭ I peak/(Vm Ϫ Erev), where Ipeak is the peak ICa,T and Erev is the extrapolated reversal potential of ICa,T. Conductance values were then normalized to the maximal conductance and fitted to the following Boltzmann equation:
where Gmax is the maximal Ca 2ϩ conductance, V0.5 is the potential at which the conductance is halfmaximally activated, and k is the slope factor.
The voltage dependence of steady-state inactivation for I Ca,T was determined with the use of a double-pulse protocol. A conditioning pulse for 1 s to various voltages ranging from Ϫ90 to Ϫ50 mV was followed by a test pulse to Ϫ40 mV for 200 ms to elicit I Ca,T. Data were normalized by dividing the test current by the maximal current elicited and fitted according to the Boltzmann equation.
The recovery of I Ca,T from inactivation was studied by applying two test pulses to Ϫ40 mV for 50 ms from a HP of Ϫ100 mV with increasing intervals from 10 to 3,000 ms every 5 s. The fractional recovery was calculated as the ratio of the current during the test pulse to the maximum current during the conditioning pulse.
PCR analysis. Total RNA of cardiac ventricles was extracted from E9.5 mouse embryos using a RNeasy Mini Kit (Qiagen; Hilden, Germany) and from E18 embryos and adult mice by the acid guanidinium-phenol-chloroform method. Single-strand cDNA was synthesized from DNase I (Boehringer; Ingelheim, Germany)-treated RNA and incubated with oligo (dT) primer and Superscript II RT (GIBCO-BRL; Gaithersburg, MD). The enzyme was then heat inactivated, and RNase H (GIBCO-BRL) was added to degrade residual RNA.
Two types PCR were carried out: conventional PCR and real-time PCR. GAPDH mRNA was used as an internal control. Primers and Taqman probes for Ca v3.1, Cav3.2, and GAPDH were designed by using Primer Express (Perkin Elmer Applied Biosystems) ( Table 1) . Conventional PCR was first performed using AmpliTaq Gold (Roche Molecular Systems). After 30 cycles of PCR, amplified fragments were resolved on a 2% agarose gel. PCR products for Ca v3.1, Cav3.2, and GAPDH genes were subcloned by TA cloning (pGEM-T Easy; Promega) and were verified by sequencing.
To quantify mRNA expression of Ca v3.1, Cav3.2, and GAPDH, we applied a real-time fluorogenic 5Ј-nuclease PCR assay, ABI Prism 7700 (Perkin Elmer Applied Biosystems). The Taqman probe contains reporter dye at the 5Ј end and quencher dye at the 3Ј end. During the PCR reaction, the 5Ј nuclease activity of AmpliTaq Gold cleaves the Taqman probe to separate the reporter dye and the quencher dye, which results in increased fluorescence of the reporter dye. Accumulation of PCR products was detected directly by monitoring the increase in fluorescence. The fluorescence signals were analyzed and converted into a relative number of copies of target molecules. Standard curves for the quantification were constructed by amplification of successive template quantity of cDNA (from 1 ϫ 10 3 to 1 ϫ 10 7 ). The threshold cycles were plotted against the logarithm of the initial molecule number of cDNA standards with linear relationships. Slope factors of Cav3.1, Cav3.2, and GAPDH were Ϫ3.275, Ϫ3.447, and Ϫ3.425 cycles/log decade, respectively. In a real-time PCR experiment, 300 ng cDNA of the sample was added to each tube.
Recently, several investigators suggested that the expression level of GAPDH mRNA could alter under cell proliferating condition. To test the suitability of GAPDH as an internal control, we investigated whether there is the existence of developmental change in GAPDH mRNA expression. We observed no significant changes in the expression GAPDH mRNA among these stages [459 ϫ 10 4 Ϯ 68 ϫ 10 4 at E9.5 (n ϭ 6), 425 ϫ 10 4 Ϯ 26 ϫ 10 4 at E18 (n ϭ 6), and 345 ϫ 10 4 Ϯ 67 ϫ 10 4 at 10 wk old (n ϭ 7); P ϭ 0.38]. Statistics. Data analysis, statistics, and curve fitting were performed with pCLAMP8 software (Axon Instruments), Origin software (Microcal Software), and Microsoft Excel computer software. Values are presented as means Ϯ SE and were analyzed by the unpaired t-test, ANOVA, and analysis of covariance. For multiple comparisons, Scheffé's F-test was followed. Differences were considered significant at P Ͻ 0.05.
RESULTS
Two components of Ca
2ϩ current in embryonic ventricular myocytes. Two components of Ca 2ϩ current were recorded from ventricular myocytes with different HPs. Figure 1 shows representative current traces recorded from an E9.5 myocyte. Depolarizing pulses to various voltages (Ϫ40 to ϩ30 mV) from a HP of Ϫ100 mV caused greater inward currents than those from a HP of Ϫ50 mV. Subtraction of the currents has revealed the presence of low-voltage-activated I Ca,T in addition to high-voltage-activated I Ca,L . Figure 2 summarizes the current-voltage relationships (I-V curves) of Ca 2ϩ current recorded from ventricular myocytes at E9.5, E18, and adult, respectively. Both in E9.5 ( Fig. 2A) and E18 ( Fig. 2B ) myocytes, the difference current (I Ca,T ) was activated negative to Ϫ40 mV and peaked at around Ϫ20 mV.
The peak I Ca,T density of E18 myocytes tended to be larger at more depolarized membrane potential than that of E9.5 myocytes, but the differences did not reach a statistical significance. In adult myocytes (Fig. 2C) , the two I-V curves from HP of Ϫ100 and Ϫ50 mV were almost superimposed, giving rise to minimal difference current at potentials more positive than Ϫ20 mV; the difference current is not the result of I Ca,T , but may reflect a partial voltage-dependent inactivation of I Ca,L , because its apparent I-V curve was proportional to the current recorded with a HP of Ϫ50 mV. Activation and inactivation properties of I Ca,T . The current properties of I Ca,T in embryonic myocytes were studied after application of nisoldipine (3 M) to eliminate I Ca,L . It was confirmed in our different series of experiments that I Ca,L in either embryonic or adult ventricular myocytes is abolished completely by 3 M nisoldipine (data not shown). In both E9.5 and E18 myocytes, I Ca,T was activated and inactivated rapidly during depolarization to Ϫ40 mV (for 200 ms) from a HP of Ϫ100 mV. The activation and inactivation time courses were fitted by single-exponential functions (Fig. 3 ). There were no significant differences in the activation ( act ) and inactivation time constants ( inac ) between the two embryonic stages.
The voltage dependence of activation and that of steadystate inactivation of I Ca,T were also studied in the presence of nisoldipine (Fig. 4A) . The activation curves of individual cells were fitted to a Boltzmann equation, and the parameters obtained were averaged. For I Ca,T recorded from E9.5 myocytes, the V 0.5 was at Ϫ40.9 Ϯ 1.1 mV and k was 5.3 Ϯ 0.3 mV (n ϭ 9). For I Ca,T recorded from E18 myocytes, V 0.5 was Ϫ38.4 Ϯ 1.1 mV and k was 5.0 Ϯ 0.5 mV (n ϭ 6). The steady-state inactivation curves analyzed similarly give rise to V 0.5 at Ϫ63.4 Ϯ 0.9 mV with a k of Ϫ4.2 Ϯ 0.5 mV for E9.5 myocytes (n ϭ 7) and V 0.5 at Ϫ60.2 Ϯ 1.3 mV with a k of Ϫ4.7 Ϯ 0.2 mV for E18 myocytes (n ϭ 7). There were no significant differences in V 0. 5 and k values between the two embryonic stages for both activation and inactivation, and the activation and steady-state inactivation curves fitted to averaged data of myocytes at E9.5 and E18 (Fig. 4A) were almost superimposed. Figure 4B illustrates time-dependent I Ca,T recovery from inactivation in the embryonic myocytes (E9.5 and E18). The fractional recovery expressed as the ratio of the current during the test pulse to the maximum current during the conditioning pulse was plotted as a function of the interpulse duration. The relations were best fitted by a double exponential function. The curve fits provided time constants fast and slow and amplitudes A fast and A slow for fast and slowly recovering current fractions, respectively. The recovery kinetics at E9.5 ( fast , 37.2 Ϯ 6.9 ms; A fast , 0.45 Ϯ 0.08; slow , 276 Ϯ 21 ms; and A slow , 0.54 Ϯ 0.07; n ϭ 6) were similar to those at E18 ( fast , 26.9 Ϯ 5.0 ms; A fast , 0.50 Ϯ 0.03; slow , 300 Ϯ 23 ms; and A slow , 0.41 Ϯ 0.05; n ϭ 8).
Ni 2ϩ sensitivity. Ni 2ϩ applied to myocytes acts as a blocker of I Ca,T . As previously reported from heterologous expression systems, the Ni 2ϩ sensitivity of Ca v 3.2-and Ca v 3.1-related current strongly differs (IC 50 ϭ 12 and Ͼ150 M, respectively) (16) . We therefore examined the effects of Ni 2ϩ at concentrations ranging from 1 to 1,000 M on I Ca,T recorded from embryonic (E9.5 and E18) ventricular myocytes. Representative records are shown in Fig. 5A . I Ca,T was measured at a test pulse to Ϫ40 mV from a HP of Ϫ100 mV in the presence of nisoldipine. Bath application of 30 M Ni 2ϩ resulted in a prompt reduction of I Ca,T amplitude to approximately half of control at both E9.5 and E18, indicating relatively high sensitivity of the current to Ni 2ϩ . Figure 5B shows the average dose-response curves obtained from E9.5 (n ϭ 10) and E18 (n ϭ 7) myocytes. The two curves were almost superimposed and IC 50 were 31 Ϯ 4 M at E9.5 and 26 Ϯ 5 M at E18.
Quantification of mRNA expression of T-type Ca 2ϩ channel ␣ 1 -subunit. Conventional RT-PCR revealed that Ca v 3.1 mRNA was hardly detectable in E9.5 but present in E18 and in the adult ventricle. On the other hand, Ca v 3.2 mRNA was prominent in E9.5, reduced in E18, and minimal in the adult Voltage-clamp experiments to measure ICa,T were carried out in the presence of nisoldipine (3 M) according to the procedure described in METHODS. Data points plotted are means Ϯ SE for E9.5 myocytes (F and OE, n ϭ 9) and for E18 myocytes (E and ‚, n ϭ 5). The solid lines represent the best fit with the Boltzmann equation for the respective averaged data. B: time dependence of recovery from inactivation of ICa,T. A two-pulse protocol with various interpulse intervals (⌬t) was used to estimate the recovery kinetics (inset). Relative peak current for the test pulse [(Itest) normalized to the maximum current (Imax) for the conditioning pulse] was plotted against ⌬t. Data points are means Ϯ SE for E9.5 myocytes (F, n ϭ 6) and for E18 myocytes (E, n ϭ 5). The solid lines represent the best fit with a double exponential function for the respective averaged data.
ventricle (Fig. 6A) . The expression of these transcripts was quantified by a real-time PCR assay. Figure 6B shows the data normalized to GAPDH mRNA (1 ϫ 10 5 molecules). At E9.5, Ca v 3.2 mRNA was expressed abundantly (7,177 Ϯ 105; n ϭ 7), whereas Ca v 3.1 mRNA expression was minimal (40 Ϯ 3; n ϭ 7). At E18, Ca v 3.1 mRNA was increased (1,226 Ϯ 121; n ϭ 7), whereas Ca v 3.2 mRNA was decreased (4,041 Ϯ 629; n ϭ 7), but it still remained to be dominant subtype. In adult ventricular tissue, a substantial level of Ca v 3.1 mRNA expression (741 Ϯ 148, n ϭ 7) was detected, whereas Ca v 3.2 mRNA expression was minimal (57 Ϯ 19, n ϭ 7).
DISCUSSION
In this study, we have described I Ca,T in ventricular myocytes isolated from murine embryonic hearts from the onset of the heart beat at E9.5 until briefly before birth (E18). The current, which is inhibited by relatively low concentration of Ni 2ϩ (IC 50 26 -31 M), can be recorded in association with the temporal expression of Ca v 3.2 mRNA. Interestingly, Ca v 3.2 mRNA is downregulated by ϳ50% during the second half of embryonic development. In 10-wk-old mice, I Ca,T is virtually absent, and Ca v 3.2 mRNA has almost disappeared. During the second half of embryonic development, Ca v 3.1 mRNA is upregulated by ϳ300-fold, although the other subtype (Ca v 3.2) mRNA remains predominant. The reverse is observed in adult myocytes: Ca v 3.1 mRNA is predominant, although its level of expression is lower than the embryonic period.
Developmental change of molecular identity. There is a considerable controversy among investigators as to the molecular identity of the T-type Ca 2ϩ channel in embryonic hearts. Our data on the dominance of Ca v 3.2 in the murine embryonic heart are in conflict with those of Cribbs et al. (3) . We were able to detect Ca v 3.1 mRNA at E18 (3), but we observed much higher Ca v 3.2 mRNA levels, and I Ca,T was more sensitive to Ni 2ϩ . Given the facts, we propose that Ca v 3.2-associated I Ca,T is predominant at least in the period directly after the onset of the heartbeat. The discrepancy could be attributed to different methods employed for I Ca,T recording (e.g., temperature and external solution) and for mRNA quantification (e.g., PCR assays, primers, and probes). We have investigated a broader age range than has been done previously. This experimental design has an advantage to shed light on the ongoing switch in Ca v 3 gene expression that occurs over somewhat prolonged period of development. It is interesting to note that as the isoform switch occurs at the mRNA level, the amount of I Ca,T is decreasing. Ca v 3.1d is a splice variant in the III-IV linker (alternate splice of exon 25) of Ca v 3.1. Because the primers and probes employed in the present study correspond to a domain in the COOH-terminal (exon [35] [36] , mRNAs of Ca v 3.1 and Ca v 3.1d should have been amplified similarly.
It was shown recently by Xu et al. (32) in mouse early embryonic hearts (E9.5) that expression of Ca v 3.1 mRNA is more abundant than that of Ca v 3.2 mRNA in tissue samples. In isolated cardiomyocytes at E9.5, unlike in the total heart, they showed a small but substantial mRNA expression only for Ca v 3.2 (Ca v 3.1 mRNA was below the level of detection). On the basis of these observations, Xu et al. (32) speculated that Ca v 3.1 at this embryonic stage could be expressed in other cell types than cardiomyocytes.
In rat hearts, both Ca v 3.1 and Ca v 3.2 transcripts of comparable amounts were shown to be expressed in middle-to-late embryonic stages (E16 -21). In a study by Larsen et al. (14) Ca v 3.2 mRNA decreased rapidly after birth and became undetectable at 5 wk, whereas Ca v 3.1 mRNA levels remained high in the postnatal periods. Ferron et al. (7) demonstrated that I Ca,T is expressed in fetal rat ventricular myocytes, but decreased soon after birth to an undetectable level. They also showed progressive decrease of Ni 2ϩ sensitivity of I Ca,T from the midembryonic stage (IC 50 ϭ 49 M at E16) to the neonatal stage (IC 50 ϭ 291 M at 1 day after birth). Ferron et al. (7) therefore suggested that the relative participation of each subunit varies during developmental stages: with a major contribution of Ca v 3.2 at E16, whereas Ca v 3.1 in newborn myocytes. These observations are concordant with our data indicating the dominance of Ca v 3.2 subunit in the mouse embryonic heart and subtype switching of transcripts from Ca v 3.2 to Ca v 3.1 after birth. Progressive decline of Ca v 3.2 transcripts during development from early gestation to adult stages in the heart has also been demonstrated in human hearts (26) .
Physiological and pathological implications. T-type Ca 2ϩ channels coexist with L-type Ca 2ϩ channels in the heart. The density of T-type Ca 2ϩ channels is 0.1-0.3/m 2 in adult guinea pig ventricular myocytes (4). Peak inward I Ca,T is Ͻ10% of I Ca,L in guinea pig ventricular myocytes (31, 36) . It is, however, much higher in canine Purkinje fibers (9) or the rabbit sinus node (6). The T-type Ca 2ϩ channel seems absent in the rabbit atrium, rabbit ventricle, rat ventricle, and human atrium (20) . I Ca,T may thus play a functional role only in the specialized conduction system of normal matured hearts. In our study, I Ca,T was also virtually absent in adult ventricular myocytes.
Because I Ca,T is prominent in embryonic hearts, it may play a role in sustaining ventricular automaticity together with hyperpolarization-activated inward current (I f ), which we described in embryonic murine ventricular myocytes previously (33) . The "pacemaker current" (I f ) disappears by ϳ80% during the second half of embryonic development, which is concomitant with the loss of ventricular automaticity. Figure 2 , however, shows that there is no significant difference in I Ca,T density between E9.5 and E18, despite the changes in Ca v 3.1 mRNA and Ca v 3.2 mRNA. It seems, therefore, that the amount of I Ca,T in the absence of substantial I f is insufficient to maintain regular ventricular automaticity in the embryonic heart.
Several studies have reported an upregulation of I Ca,T in adult ventricular myocytes after experimentally induced hypertrophy (19, 24) or myocardial infarction (11) . Information available for the molecular identity of such reexpressed I Ca,T is still limited. In rat model of myocardial infarction, an increase of I Ca,T was associated with an upregulation of Ca v 3.1 mRNA (11) . On the other hand, I Ca,T recorded from ventricular myocytes of rat with pressure overload-induced hypertrophy (19) and that of a genetically determined cardiomyopathic hamster (30) showed relatively high Ni 2ϩ sensitivity (IC 50 ϭ 40 -50 M), suggesting a substantial contribution of Ca v 3.2 subunit to the reexpressed I Ca,T . An increase of I Ca,T in those diseased hearts could be arrhythmogenic through an increase of action potential duration, an induction of early and delayed afterdepolarization (27) , or an enhancement of electrical and structural remodeling (5, 28) .
Limitations. In our data, I Ca,T recorded from E9.5 and E18 showed similar electrophysiological properties in terms of current density, kinetics of activation/inactivation, voltage dependence of activation, steady-state inactivation, and recovery kinetics from inactivation. This does not parallel the mRNA expression; Ca v 3.2 mRNA amount decreased, whereas the Ca v 3.1 mRNA amount increased from the early to the late embryonic period. An electrophysiological signature to discriminate the cloned Ca v 3.1 and Ca v 3.2 channels is the recovery kinetics from inactivation: Ca v 3.1 recovers more rapidly than Ca v 3.2 (13, 21) . If participation of Ca v 3.1 to the functional T-type Ca 2ϩ channels are increased from E9.5 to E18 in response to altered expression of mRNA amounts, it would cause a faster recovery from inactivation of I Ca,T in E18 myocytes. In adult myocytes, no I Ca,T was recorded despite substantial amount Ca v 3.1mRNA. These discrepancies may be interpreted in part by developmental changes of posttranscriptional and/or posttranslational regulations. Quantification of Ca v 3.1 and Ca v 3.2 protein amounts in different developmental stages will be required to get an insight into these regulations. We were unable to quantify the protein amounts, because there are no specific and reliable antibodies commercially available for the two subunits. Another possibility is a regulation of functional T-type Ca 2ϩ channel by auxiliary subunits, known to modulate ionic current like I Ca,L (23) . Further studies investigating these issues should be very useful to increase our understanding on expression of I Ca,T in developing mammalian hearts.
